Ascent Group’s AstraZeneca AZN Stock Holding History

Ascent Group’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.52M	Sell	8,010 -246	-3%	-$46.3K	0.05%	309
2026 Q1	$1.63M	Buy	8,256 +372	+5%	+$71.7K	0.06%	280
2025 Q4	$1.45M	Sell	7,884 -374	-5%	-$65.6K	0.05%	302
2025 Q3	$1.27M	Buy	8,258 +225	+3%	+$34.1K	0.04%	324
2025 Q2	$1.12M	Hold	8,033	–	–	0.04%	313
2025 Q1	$1.18M	Buy	+8,033	New	+$1.16M	0.05%	308
2023 Q2	–	Sell	-1,939	Closed	-$269K	–	454
2023 Q1	$269K	Sell	1,939 -117	-6%	-$15.7K	0.03%	417
2022 Q4	$279K	Buy	2,056 +91	+5%	+$11.4K	0.03%	403
2022 Q3	$231K	Sell	1,965 -1,236	-39%	-$157K	0.03%	430
2022 Q2	$424K	Sell	3,201 -174	-5%	-$22.8K	0.05%	329
2022 Q1	$448K	Buy	3,375 +523	+18%	+$62.7K	0.05%	324
2021 Q4	$337K	Buy	+2,852	New	+$336K	0.04%	360

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ascent Group's AZN Position: Q2 2026 in Review

Ascent Group reduced its AstraZeneca (AZN) stake by 3% in Q2 2026, selling an estimated $46.3K and leaving 8,010 shares worth $1.52M. The position accounts for 0.05% of the portfolio, ranked #309.

Ascent Group first reported a position in AZN in Q4 2021 and has held it in 12 quarters since. The position peaked at $1.63M in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Ascent Group held 8,010 shares of AstraZeneca worth $1.52M as of Q2 2026.
Ascent Group sold 246 AstraZeneca shares in Q2 2026, an estimated $46.3K.
AstraZeneca made up 0.05% of Ascent Group's portfolio in Q2 2026, its #309 holding.
Ascent Group first reported a position in AstraZeneca in Q4 2021 and has held it in 12 quarters since.
Ascent Group's AstraZeneca position peaked at $1.63M in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Ascent Group's 13F filing for Q2 2026, filed 3 Aug 2026.